CURRICULUM VITAE

Yasufumi Katanasaka, Ph.D

Assistant Professor
Division of Molecular Medicine
Graduate School of Pharmaceutical Sciences
University of Shizuoka
52-1 Yada, Shizuoka 422-8526, Japan
Phone: +81-54-264-5766
Fax: +81-54-264-5764
E-mail: katana@u-shizuoka-ken.ac.jp
WORK EXPERIENCE
Assistant Professor, April 2010 to present
Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of
Shizuoka, Shizuoka, Japan
Projects⚫ Molecular-targeted therapy of chronic heart failure by natural compounds⚫ Analysis of molecular mechanism by which PRMT5/MEP50 methylsome complex
regulates heart failure⚫ Clinical studies to assess food function in lifestyle diseases
Postdoctoral fellowship, September 2016 to August 2017
Boston University School of Medicine, Boston, MA, USA
Projects⚫ Clonal hematopoiesis in heart failure⚫ Gene manipulation in hematopoietic stem cells
Postdoctoral fellowship, April 2008 to March 2010
Shien-Lab, National Cancer Center Hospital, Tokyo, Japan
Projects⚫ Molecular-targeted therapy of PI3K/mTOR inhibitor in lung cancer⚫ Analysis of molecular mechanism of EGFRvIII-induced angiogenesis in glioma⚫ Anti-lymphangiogenesis therapy using molecular-targeted drugs
EDUCATION
Ph.D. in Pharmaceutical Science, March 2008
Department of Medical Biochemistry, Graduate School of Pharmaceutical Sciences, University of
Shizuoka, Shizuoka, Japan
Dissertation title: Proteomic identification of novel angiogenesis-related proteins and– １ –its application to antineovascular therapy⚫ Proteomic analysis of VEGF-activated endothelial cells using 2D-DIGE⚫ Molecular-targeted drug delivery using liposomes and cancer therapy
Supervisors: Prof. N. Oku and Prof. N. Ohashi
Master of Sciences in Pharmaceutical Science, March 2005
Department of Medical Biochemistry, Graduate School of Pharmaceutical Sciences, University of
Shizuoka, Shizuoka, Japan
Dissertation title: Proteomic analysis for identification of angiogenesis-related proteins
Supervisors: Prof. N. Oku and Prof. N. Ohashi
Bachelor of Sciences in Pharmaceutical Science, March 2003
Faculty of Pharmaceutical Science, University of Shizuoka, Shizuoka, Japan
PUBLICATIONS
1.

2.

3.

4.

5.

6.

7.

8.

Kawase, Y., Sunagawa, Y., Shimizu, K., Funamoto, M., Hamabe-Horiike, T., Katanasaka, Y., Shimizu,
S., Hawke, P., Mori, K., Komiyama, M., Hasegawa, K., & Morimoto, T. (2023). 6-Shogaol, an Active
Component of Ginger, Inhibits p300 Histone Acetyltransferase Activity and Attenuates the Developmentof Pressure-Overload-Induced Heart Failure. Nutrients, 15(9), 2232.
Iwashita, M., Shioi, R., Sugiyama, M., Hashizume, K., Kan, T., Naito, S., Takai, H., Kawase, Y.,
Hamabe-Horiike, T., Katanasaka, Y, Sunagawa, Y., & Morimoto, T. (2023). Monodemethylated
Metabolites of Orally Administered Nobiletin: Identification and Quantitation in Rat Plasma and Tissues.
Journal of Agricultural and Food Chemistry, 71(26), 10028-10036.
Katanasaka, Y, Sunagawa, Y., Miyazaki, Y., Funamoto, M., Shimizu, S., Shimizu, K., Yamakage, H.,
Satoh-Asahara, N., Toyama, K., Sabashi, T., Suzuki, M., Hamabe-Horiike, T., Komiyama, M., Wada, H.,
Mori, K., Hasegawa, K., & Morimoto, T. (2022). Ameliorating prediabetic subject status via fermented
tea supplementation: A randomized, double-blind, parallel-group comparison study. Journal of
Functional Foods, 97, 105257.
Katanasaka, Y, Saito, A., Sunagawa, Y., Sari, N., Funamoto, M., Shimizu, S., Shimizu, K., Akimoto, T.,
Ueki, C., Kitano, M., Hasegawa, K., Sakaguchi, G., & Morimoto, T. (2022). ANGPTL4 Expression Is
Increased in Epicardial Adipose Tissue of Patients with Coronary Artery Disease. Journal of Clinical
Medicine, 11(9), 2449.
Sunagawa, Y., Kawaguchi, S., Miyazaki, Y., Katanasaka, Y, Funamoto, M., Shimizu, K., Shimizu, S.,
Hamabe-Horiike, T., Kawase, Y., Komiyama, M., Mori, K., Murakami, A., Hasegawa, K., & Morimoto,T. (2022). Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart
failure by activating PPARα in rats. Phytomedicine, 107, 154457.
Sunagawa, Y., Katayama, A., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Katanasaka, Y
Miyazaki, Y., Hosomi, R., Hasegawa, K., & Morimoto, T. (2022). The polyunsaturated fatty acids, EPA
and DHA, ameliorate myocardial infarction-induced heart failure by inhibiting p300-HAT activity inrats. The Journal of Nutritional Biochemistry, 106, 109031.
Shimizu, S., Sunagawa, Y., Hajika, N., Yorimitsu, N., Katanasaka, Y, Funamoto, M., Miyazaki, Y., Sari,
N., Shimizu, K., & Hasegawa, K. (2022). Multimerization of the GATA4 transcription factor regulates
transcriptional activity and cardiomyocyte hypertrophic response. International Journal of Biological
Sciences, 18(3), 1079-1095.
Ono, M., Sunagawa, Y., Mochizuki, S., Katagiri, T., Takai, H., Iwashimizu, S., Inai, K., Funamoto, M.,
Shimizu, K., Shimizu, S., Katanasaka, Y, Komiyama, M., Hawke, P., Hara, H., Arakawa, Y., Mori, K.,– ２ –Asai, A., Hasegawa, K., & Morimoto, T. (2022). Chrysanthemum morifolium Extract Ameliorates
Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis. Cancers, 14(3), 683.
9. Mittal, S., Komiyama, M., Ozaki, Y., Yamakage, H., Satoh-Asahara, N., Yasoda, A., Wada, H.,
Funamoto, M., Shimizu, K., Miyazaki, Y., Katanasaka, Y, Sunagawa, Y., Morimoto, T., Takahashi, Y.,
Nakayama, T., & Hasegawa, K. (2022). Gingival bleeding and pocket depth among smokers and therelated changes after short-term smoking cessation. Acta Odontologica Scandinavica, 80(4), 258-263.
10. Katagiri, T., Sunagawa, Y., Maekawa, T., Funamoto, M., Shimizu, S., Shimizu, K., Katanasaka, Y,
Komiyama, M., Hawke, P., Hara, H., Mori, K., Hasegawa, K., & Morimoto, T. (2022). Ecklonia
stolonifera Okamura Extract Suppresses Myocardial Infarction-Induced Left Ventricular Systolic
Dysfunction by Inhibiting p300-HAT Activity. Nutrients, 14(3), 580.
11. Funamoto, M., Sunagawa, Y., Katanasaka, Y, Kato, T., Funada, J., Ajiro, Y., Komiyama, M., Akao, M.,
Yasoda, A., Yamakage, H., Satoh-Asahara, N., Wada, H., Ikeda, Y., Morimoto, T., & Hasegawa, K.
(2022). Effects of high-absorption curcumin for the prevention of hypertensive heart disease: adouble-blind, placebo-controlled, randomized clinical study. European Heart Journal Open, 2(5).
12. Funamoto, M., Sunagawa, Y., Gempei, M., Shimizu, K., Katanasaka, Y, Shimizu, S., Hamabe-Horiike,
T., Appendino, G., Minassi, A., Koeberle, A., Komiyama, M., Mori, K., Hasegawa, K., & Morimoto, T.
(2022). Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1
Complex. Pharmaceutics, 14(6), 1269.
13. Yura, Y., Miura-Yura, E., Katanasaka, Y, Min, K.-D., Chavkin, N., Polizio, A. H., Ogawa, H., Horitani,K., Doviak, H., Evans, M. A., Sano, M., Wang, Y., Boroviak, K., Philippos, G., Domingues, A. F.,
Vassiliou, G., Sano, S., & Walsh, K. (2021). The Cancer Therapy-Related Clonal Hematopoiesis Driver
Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice. Circulation Research,
129(6), 684-698.
14. Sari, N., Katanasaka, Y (co-fitst author), Sugiyama, Y., Sunagawa, Y., Miyazaki, Y., Funamoto, M.,
Shimizu, S., Shimizu, K., Murakami, A., Mori, K., Wada, H., Hasegawa, K., & Morimoto, T. (2021).
Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting
cardiac hypertrophy and fibrosis. Phytomedicine, 92, 153744.
15. Sari, N., Katanasaka, Y, Sugiyama, Y., Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K.,
Shimizu, S., Hasegawa, K., & Morimoto, T. (2021). Alpha Mangostin Derived from Garcinia
magostana Linn Ameliorates Cardiomyocyte Hypertrophy and Fibroblast Phenotypes in Vitro.
Biological and Pharmaceutical Bulletin, 44(10), 1465-1472.
16. Katanasaka, Y, Yoshida, N., Naitou, H., Naruta, R., Miyazaki, Y., Sunagawa, Y., Funamoto, M.,
Shimizu, K., Shimizu, S., Sari, N., Yamakage, H., Sato-Asahara, N., Hasegawa, K., & Morimoto, T.
(2021). Effect of Theaflavin on Oral Bacteria in Japanese Subjects: A Randomized, Placebo-Controlled,
Double-Blind Study. Journal of Medicinal Food, 24(11), 1186-1190.
17. Katanasaka, Y, Hirano, S., Sunagawa, Y., Miyazaki, Y., Sato, H., Funamoto, M., Shimizu, K., Shimizu,
S., Sari, N., Hasegawa, K., & Morimoto, T. (2021). Clinically Administered Doses of Pitavastatin andRosuvastatin Effects on Myocardial Hypertrophy Using Cultured Cardiomyocytes. International Heart
Journal, 62(6), 1379-1386.
18. Sunagawa, Y., Shimizu, K., Katayama, A., Funamoto, M., Shimizu, K., Nurmila, S., Shimizu, S.,
Miyazaki, Y., Katanasaka, Y, & Hasegawa, K. (2021). Metformin suppresses phenylephrine-induced
hypertrophic responses by inhibiting p300-HAT activity in cardiomyocytes. J Pharmacol Sci, 147(2),169-175.
19. Sunagawa, Y., Miyazaki, Y., Funamoto, M., Shimizu, K., Shimizu, S., Nurmila, S., Katanasaka, Y, Ito,
M., Ogawa, T., & Ozawa-Umeta, H. (2021). A novel amorphous preparation improved curcuminbioavailability in healthy volunteers: A single-dose, double-blind, two-way crossover study. Journal of
Functional Foods, 81, 104443.

– ３ –20. Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Katanasaka, Y, Miyazaki, Y., Kakeya,
H., Hasegawa, K., & Morimoto, T. (2021). Curcumin, an Inhibitor of p300-HAT Activity, Suppresses
the Development of Hypertension-Induced Left Ventricular Hypertrophy with Preserved Ejection
Fraction in Dahl Rats. Nutrients, 13(8), 2608.
21. Shimizu, K., Sunagawa, Y., Funamoto, M., Honda, H., Katanasaka, Y, Murai, N., Kawase, Y., Hirako,
Y., Katagiri, T., Yabe, H., Shimizu, S., Sari, N., Wada, H., Hasegawa, K., & Morimoto, T. (2021). The
Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic
Dysfunction via Inhibition of the ERK1/2;GATA4 Signaling Pathway. Pharmaceuticals, 14(12), 1268.
22. Mittal, S., Komiyama, M., Ozaki, Y., Yamakage, H., Satoh-Asahara, N., Yasoda, A., Wada, H.,
Funamoto, M., Shimizu, K., Miyazaki, Y., Katanasaka, Y, Sunagawa, Y., Morimoto, T., Takahashi, Y.,
Nakayama, T., & Hasegawa, K. (2021). Gingival bleeding and pocket depth among smokers and therelated changes after short-term smoking cessation. Acta Odontologica Scandinavica, 1-6.
23. Komiyama, M., Ozaki, Y., Miyazaki, Y., Katanasaka, Y, Sunagawa, Y., Funamoto, M., Shimizu, K.,
Yamakage, H., Sato-Asahara, N., & Yasoda, A. (2021). Neutrophil/lymphocyte ratio is correlated withlevels of inflammatory markers and is significantly reduced by smoking cessation. Journal ofInternational Medical Research, 49(6), 03000605211019223.
24. Funamoto, M., Sunagawa, Y., Katanasaka, Y, Shimizu, K., Miyazaki, Y., Sari, N., Shimizu, S., Mori,
K., Wada, H., Hasegawa, K., & Morimoto, T. (2021). Histone Acetylation Domains Are Differentially
Induced during Development of Heart Failure in Dahl Salt-Sensitive Rats. International journal ofmolecular sciences, 22(4), 1771.
25. Shimizu, K., Sunagawa, Y., Funamoto, M., Wakabayashi, H., Genpei, M., Miyazaki, Y., Katanasaka, Y,
Sari, N., Shimizu, S., Katayama, A., Shibata, H., Iwabuchi, Y., Kakeya, H., Wada, H., Hasegawa, K., &Morimoto, T. (2020). The Synthetic Curcumin Analogue GO-Y030 Effectively Suppresses theDevelopment of Pressure Overload-induced Heart Failure in Mice. Sci Rep, 10(1), 7172.
26. Sari, N., Katanasaka, Y, Honda, H., Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu,
S., Wada, H., Hasegawa, K., & Morimoto, T. (2020). Cacao Bean Polyphenols Inhibit Cardiac
Hypertrophy and Systolic Dysfunction in Pressure Overload-induced Heart Failure Model Mice. Planta
Medica, 86(17), 1304-1312.
27. Miyazaki, Y., Katanasaka, Y (co-first author), Tsutsui, Y., Sunagawa, Y., Funamoto, M., Shimizu, K.,
Shimizu, S., Sari, N., Yamakage, H., Satoh-Asahara, N., Toyama, K., Suzuki, M., Shimizu, A., Wada, H.,
Hasegawa, K., & Morimoto, T. (2020). A Randomized Placebo-controlled, Double-blind Study ofKosen-cha, a Polymerized Catechin-rich Green Tea, for Obesity in Pre-obese Japanese Subjects. BPB
Reports, 3(6), 202-207.
28. Katanasaka, Y, Miyazaki, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Shimizu, S., Sari, N., Shimizu,
Y., Wada, H., Hasegawa, K., & Morimoto, T. (2020). Kosen-cha, a Polymerized Catechin-Rich Green
Tea, as a Potential Functional Beverage for the Reduction of Body Weight and Cardiovascular Risk
Factors: A Pilot Study in Obese Patients. Biol Pharm Bull, 43(4), 675-681.
29. Wang, Y., Sano, S., Oshima, K., Sano, M., Watanabe, Y., Katanasaka, Y, Yura, Y., Jung, C., Anzai, A.,
Swirski, F. K., Gokce, N., & Walsh, K. (2019). Wnt5a-Mediated Neutrophil Recruitment Has an
Obligatory Role in Pressure Overload-Induced Cardiac Dysfunction. Circulation, 140(6), 487-499.
30. Sano, S., Wang, Y., Yura, Y., Sano, M., Oshima, K., Yang, Y., Katanasaka, Y, Min, K. D., Matsuura, S.,
Ravid, K., Mohi, G., & Walsh, K. (2019). JAK2 (V617F) -Mediated Clonal Hematopoiesis Accelerates
Pathological Remodeling in Murine Heart Failure. JACC Basic Transl Sci, 4(6), 684-697.
31. Funamoto, M., Shimizu, K., Sunagawa, Y., Katanasaka, Y, Miyazaki, Y., Kakeya, H., Yamakage, H.,
Satoh-Asahara, N., Wada, H., Hasegawa, K., & Morimoto, T. (2019). Effects of Highly AbsorbableCurcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus. J
Diabetes Res, 2019, 8208237.

– ４ –32. Sunagawa, Y., Okamura, N., Miyazaki, Y., Shimizu, K., Genpei, M., Funamoto, M., Shimizu, S.,
Katanasaka, Y, Morimoto, E., Yamakage, H., Komiyama, M., Satoh-Asahara, N., Wada, H., Suzuki, M.,
Hasegawa, K., & Morimoto, T. (2018). Effects of Products Containing Bacillus subtilis var. natto on
Healthy Subjects with Neck and Shoulder Stiffness, a Double-Blind, Placebo-Controlled, Randomized
Crossover Study. Biol Pharm Bull, 41(4), 504-509.
33. Sunagawa, Y., Funamoto, M., Sono, S., Shimizu, K., Shimizu, S., Genpei, M., Miyazaki, Y.,
Katanasaka, Y, Morimoto, E., Ueno, M., Komiyama, M., Kakeya, H., Wada, H., Hasegawa, K., &Morimoto, T. (2018). Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity andsuppress hypertrophic responses in cardiomyocytes. J Pharmacol Sci, 136(4), 212-217.
34. Sano, S., Oshima, K., Wang, Y., MacLauchlan, S., Katanasaka, Y, Sano, M., Zuriaga, M. A.,
Yoshiyama, M., Goukassian, D., Cooper, M. A., Fuster, J. J., & Walsh, K. (2018). Tet2-Mediated Clonal
Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3Inflammasome. Journal of the American College of Cardiology, 71(8), 875-886.
35. Sano, S., Oshima, K., Wang, Y., Katanasaka, Y, Sano, M., & Walsh, K. (2018). CRISPR-MediatedGene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular
Disease. Circulation Research, 123(3), 335-341.
36. Suzuki, H., Katanasaka, Y, Sunagawa, Y., Miyazaki, Y., Funamoto, M., Wada, H., Hasegawa, K., &Morimoto, T. (2016). Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy byregulating the interaction between p300 and GATA4. Biochimica et Biophysica Acta, 1862(9),1544-1557.
37. Sunagawa, Y., Katanasaka, Y, Wada, H., Hasegawa, K., & Morimoto, T. (2016). Functional Analysis of
GATA4 Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics
Approach. Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan, 136(2), 151-156.
38. Nakamura K, Sano S, Fuster JJ, Kikuchi R, Shimizu I, Ohshima K, Katanasaka Y, Ouchi N, Walsh K.
Secreted frizzled-related protein 5 diminishes cardiac inflammation and protects the heart fromischemia-reperfusion injury. J Biol Chem. 2016;291:2566-2575.
39. Sunagawa Y, Katanasaka Y, Wada H, Hasegawa K, Morimoto T. Functional Analysis of GATA4
Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics Approach.
Yakugaku Zasshi. 2016;136:151-156.
40. Morimoto T, Katanasaka Y, Sunagawa Y, Hirano S, Miyazaki Y, Funamoto M, Hojo Y, Suzuki H,
Morimoto E, Ueno M, Shimatsu A, Satoh-Asahara N, Yamakage H, Wada H, Hasegawa K. Effects ofstatins on left ventricular diastolic function in patients with dyslipidemia and diastolic dysfunction(STAT-LVDF study). Biol Pharm Bull. 2015;38:1404-1409
41. Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N, Hojo Y, Suzuki H, Doi
O, Yokoji T, Morimoto E, Takahashi T, Ozawa H, Imaizumi A, Ueno M, Kakeya H, Shimatsu A, Wada
H, Hasegawa K, Morimoto T. Colloidal submicron-particle curcumin exhibits high absorption
efficiency-a double-blind, 3-way crossover study. Journal of nutritional science and vitaminology.
2015;61:37-44
42. Kikuchi R, Nakamura K, MacLauchlan S, Ngo D, Shimizu I, Fuster J, Katanasaka Y, et al: An
anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.
Nature Medicine. 2014;20:1464-1471
43. Sunagawa Y, Sono S, Katanasaka Y, et al. Optimal Dose-Setting Study of Curcumin for Improvementof Left Ventricular Systolic Function After Myocardial Infarction in Rats. J Pharmacol Sci.
2014;126:329-336.
44. Katanasaka Y, et al: Synergistic anti-tumor effects of a novel phosphatidyl inositol-3
kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lungcancer cell lines. Cancer Lett. 347:196-203, 2014.
45. Katanasaka Y, et al. Epidermal growth factor receptor variant type iii markedly accelerates– ５ –angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression inmalignant glioma. Molecular cancer;12:31, 2013
46. Katanasaka Y, et al. Application of curcumin to heart failure therapy. Biol Pharm Bull; 36: 13-17,
2013.
47. Sugiyama T, Asai T, Nedachi YM, Katanasaka Y, et al: Enhanced active targeting via cooperative
binding of ligands on liposomes to target receptors. PLoS One; 8:e67550, 2013.
48. Morimoto T, Sunagawa Y, Katanasaka Y, et al.: Drinkable preparation of Theracurmin exhibits highabsorption efficiency--a single-dose, double-blind, 4-way crossover study. Biol Pharm Bull.; 36:
1708-14. 2013
49. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, et al, Tamura K. Efficacy of everolimus, a novel
mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci; 103:1665-71, 2012.
50. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, Katanasaka Y, et al.
A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure
after myocardial infarction in rats. Biol Pharm Bull; 35:139-44, 2012
51. Kodera Y, Katanasaka Y, et al, Sunitinib inhibits lymphatic endothelial cell functions and lymph nodemetastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Breast Cancer Res; 13:R66, 2011.
52. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, et al. A natural p300-specific histone
acetyltransferase inhibitor, curcumin, in addition to angiotensin converting enzyme inhibitor exerts
beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J;
75:2151-9, 2011.
53. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, etal. Innovative preparation of curcumin for improved oral bioavailability, Biol Pharm Bull; 34:660-5,
2011.
54. Taguchi F, Kodera Y, Katanasaka Y, et al. Efficacy of RAD001 (everolimus) against advanced gastriccancer with peritoneal dissemination. Invest New Drugs; 29:660-5, 2011.
55. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, and Oku N.
Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int J
Cancer; 127:2685-98, 2010.
56. Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, and Oku N. A novel DDS strategy,"dual-targeting", and its application for antineovascular therapy. Cancer Lett; 287:165-71, 2010.
57. Katanasaka Y, Ida T, Asai T, Maeda N, and Oku N. Effective delivery of an angiogenesis inhibitor byneovessel-targeted liposomes. Int J Pharm; 360:219-24, 2008.
58. Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, and Oku N. Antiangiogenic
cancertherapyusing
tumor
vasculature-targeted
liposomes
encapsulating
3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett; 270:260-68,
2008.
59. Asai T, Miyazawa S, Maeda N, Hatanaka K, Katanasaka Y, Shimizu K, Shuto S, and Oku N.
Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal
DPP-CNDAC. Cancer Sci; 99:1029-33, 2008.
60. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H,
Nango M, and Oku N. Disappearance of the angiogenic potential of endothelial cells caused by
Argonaute2 knockdown. Biochem Biophys Res Commun; 368:243-8, 2008.
61. Katanasaka Y, Asai T, Naitou H, Ohashi N, and Oku N. Proteomic characterization of angiogenic
endothelial cells stimulated with cancer cell-conditioned medium. Biol Pharm Bull; 30:2300-7, 2007.
62. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, and Oku N.
Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int– ６ –J Cancer; 108:301-6, 2004.

CHAPTERS IN BOOKS
1.
2.
3.

Katanasaka, Y. (2017). [Development of Targeted Pharmacotherapy for Cardiovascular Disease].
Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan, 137(11), 1349-1353.
Katanasaka Y and Morimoto T. Green tea in antiaging. In Antiaging medicine, p.23-27. Tokyo:
Medical view, ISBN: 9784815917425. (In Japanese), 2015.
Katanasaka Y and N. Oku. Integrin. In Liver Metastasis, M. Monden and N. Matsuura,eds., p. 23-27.
Tokyo: Nagai Syoten, ISBN: 9784815917425. (In Japanese), 2005.

GRANTS & AWARDS
1.
2.

Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research(C) 19K07325, 2019-2021

3.
4.
5.

Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientist 16K18876, 2016-2018

Effect of a tea component Theaflavin on oral flora, JST A-STEP, 18088769, 2018 -2019
Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientist 25860052, 2013-2015
Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientist (Start-up) 22890153,
2010-2011

6. The Sapporo Bioscience Foundation, 2023
7. The Takeda Science Foundation, 2022-2024
8. The Tojuro Iijima Foundation for Food Science and Technology, 2022 年
9. The Nakatomi Foundation, 2022-2023
10. he SENSHIN Medical Research Foundation, 2021-2022
11. The Mochida Memorial Foundation for Medical and Pharmaceutical Research, 2018-2019
12. The Hamamatsu Foundation for Science and Technology Promotion, 201813. Shizuoka city, 2018-2023 年
14. The Consortium of Universities & Local Communities in Shizuoka, 201815. the MSD Life Science Foundation, 2018-2019
16. The Kobayashi Foundation, 2018-2020
17. The Kanae Foundation for the Promotion of Medical Science, 201718. The Takeda Science Foundation, 201719. The Hamamatsu Foundation for Science and Technology Promotion, grant number 15-556. 2016
20. The Suzuken Memorial Foundation, 2016
21. The Tokyo Biochemistry Foundation, 201622. YOKOYAMA Foundation for Clinical Pharmacology, 2015
1.
2.
3.
4.

Young Investigator Award, Japanese Society of Pharmaceutical Sciences, 2016.
Poster Award, 1st Japan ISCP, Kyoto, Japan, 2015.
Poster Award, 18th ISCP, Roma, Italy, 2013.
Young Investigator Award, 7th China-Japan Cardiovascular Forum, 2010.

– ７ –

5.

Poster Award, 11th Shizuoka Forum on Health and Longevity, Shizuoka, Japan, 2006.

– ８ –